ZEAL
NASDAQZealand Pharma A/S
News · 26 weeks29+20%
2025-11-022026-04-26
Mix1690d
- Other10(63%)
- Earnings4(25%)
- Dividends1(6%)
- Leadership1(6%)
Latest news
25 items- PRZealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial resultsPress Release – No. 8 / 2026 Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results Copenhagen, Denmark and Boston, Massachusetts, April 30, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on May 7, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter / first three months of 2026. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The pre
- PRZealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight managementCompany announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management Phase 3 trials for chronic weight management planned for initiation in the second half of 2026Petrelintide demonstrated double-digit weight loss with placebo-like tolerability in the ZUPREME-1 Phase 2 trialZealand Pharma and Roche aim to unlock the full value potential of petrelintide providing a highly tolerable option for people living with overweight and obesity Copenhagen, Denmark, April 29, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced
- PRZealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trialCompany announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity or overweight in Phase 3 trial In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health1In addition to
- PRTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCompany announcement – No. 8 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharm
- PRZealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2026Company announcement – No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces the implementation of long-term incentive programs for 2026 (the "LTIP") for the Board of Directors, Corporate Management and employees of Zealand Pharma, in accordance with the Company's remuneration policy and overall guidelines for incentive pay, as adopted at the annual general meeting held on March 20, 202
- PRZealand Pharma Appoints Eric Rojas as Vice President and Head of Investor RelationsPress release – No. 7 / 2026 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Bringing significant experience from Vertex Pharmaceuticals and Shire Copenhagen, Denmark and Boston, Massachusetts, April 14, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced the appointment of Eric Rojas, Vice President, Investor Relations, effective April 15, 2026. Eric will report to Henriette Wennicke, Chief Financial Officer, and will be based in Massachusetts, U.S. Eric brings more than two decades of experience in investor relations and finance, having supported both US
- PRTotal number of shares and voting rights in Zealand Pharma as of March 31, 2026Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S ("Zealand Pharma" or "the Company") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 4 / 2026, dated March 19, 2026, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Fo
- PRResolutions from Zealand Pharma's Annual General Meeting 2026Company announcement – No. 5 / 2026 Resolutions from Zealand Pharma's Annual General Meeting 2026 Copenhagen, Denmark, March 26, 2026 - Zealand Pharma A/S ("Zealand Pharma" or the "Company") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today held its Annual General Meeting of 2026 as a partly electronic and partly physical general meeting (hybrid meeting). At the Annual General Meeting, all proposals presented to the Annual General Meeting were approved, save for the non-binding advisory vote on the remuneration report under item 7 on the agenda. Resolutions considered at the Annual General Meeting: Annual ReportThe Annual Genera
- PRZealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine CreationPress release – No. 6 / 2026 Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation New research hub in Cambridge, Massachusetts, in the greater Boston area, expands global discovery capabilities, combining Zealand Pharma's more than 25 years of expertise in peptides and metabolic health with Boston's biotech innovation ecosystem. Copenhagen, Denmark and Boston, Massachusetts, March 24, 2026 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced the establishment of a new research hub in Cambridge, Massachusetts, in
- PRZealand Pharma increases its share capital as a result of the exercise of employee warrantsCompany announcement – No. 4 / 2026 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 19, 2026 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 10,530 divided into 10,530 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under one of Zealand Pharma's employee warrant programs. Employee warrant programs are par
- PRZealand Pharma to participate in upcoming investor conferences in March 2026Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the company will participate in the following investor conferences in March 2026. 2026 Jefferies Biotech on the Beach Summit, March 9-11 in Miami Adam Steensberg, President and Chief Executive Officer, will host investor meetings on Tuesday, March 10. Barclays 28th Annual Global Healthcare Conference, March 10-12 in Miami Adam Steensberg, President and Chief Executive Officer, will host investor meetings
- PRZealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesityCompany announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerabilityAt the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse eventsThe data reinforce further development of petrelintide in chronic weight management as monotherapy and as a combination partnerZealand Pharma will host a conference call today at 8:30 PM CET /
- PRZealand Pharma convenes its Annual General Meeting 2026Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET) / 9:00 (ET) The Annual General Meeting will be held as a partly electronic general meeting (hybrid meeting), allowing shareholders to participate either electronically or in person. The meeting
- PRZealand Pharma Announces Financial Results for the Full Year 2025Company announcement – No. 1 / 2026 Zealand Pharma Announces Financial Results for the Full Year 2025 2025 marked a quantum leap for Zealand Pharma, with a transformative partnership for petrelintide, strong clinical progress, and organizational readiness, setting the stage for catalyst-rich and defining 2026 Entered a historic and transformative collaboration and license agreement with Roche to unlock the full potential of petrelintide as a future foundational therapy for weight management, aiming to establish the leading amylin-based franchise Positioned for the most catalyst-rich year in the company's history, including Phase 2 petrelintide data from the ZUPREME program and Phase 3 su
- PRZealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830Press release – No. 4 / 2026 Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830 Single doses of ZP9830 were well tolerated, with no serious or severe adverse events or dose-limiting safety findings observed at any dose levelZP9830 exhibited a pharmacokinetic profile in line with predictions based on preclinical data, and exploratory pharmacodynamic biomarkers showed robust, dose-dependent activity consistent with Kv1.3 target engagementZP9830 is a highly potent and selective Kv1.3 channel blocker with potential to address a broad range of immune-mediated inflammatory disordersDevelopment program is progressing rapidly and as planned, with Phase 1a
- PRZealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial resultsPress Release – No. 3 / 2026 Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on February 19, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A sess
- PRZealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategyPress release – No. 2 / 2026 Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy Access to Gefion, Denmark's flagship AI supercomputer, gives Zealand Pharma access to unprecedented computational power, enabling large-scale modeling, prediction, and optimization of drug candidatesAgreement will support Zealand Pharma's Metabolic Frontier 2030 strategy to deliver five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030 Copenhagen, Denmark, January 9, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming t
- PRZealand Pharma to present at the J.P. Morgan Healthcare ConferencePress release – No. 1 / 2026 Zealand Pharma to present at the J.P. Morgan Healthcare Conference Copenhagen, Denmark, January 5, 2026 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced that the Company will participate in the 44th J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, California. Adam Steensberg, President and Chief Executive Officer, will take part in a presentation and fireside chat on Wednesday January 14 at 1:30pm PST / 10:30pm CET. A live audio webcast will be available at: https://jpmorgan.metameetings.net/events/healthcare2
- PRTotal number of shares and voting rights in Zealand Pharma as of December 31, 2025Company announcement – No. 27 / 2025 Total number of shares and voting rights in Zealand Pharma as of December 31, 2025 Copenhagen, Denmark, December 31, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 25 / 2025 dated December 11, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee war
- PRTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCompany announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 19, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology transforming the future of metabolic health, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/
- PRZealand Pharma increases its share capital as a result of the exercise of employee warrantsCompany announcement – No. 25 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78),), a biotechnology company transforming the future of metabolic health, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 150,317 divided into 150,317 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma's incentive scheme. Each
- PRZealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic healthPress release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research site in Boston to combine our +25-year peptide heritage with AI-driven drug discovery, advanced automation, and next-generation molecule creation Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 2004
- PROTR Therapeutics and Zealand Pharma enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseasesCollaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseasesOTR Therapeutics will receive an initial upfront payment of USD 20 million, which may increase to USD 30 million under certain pre-agreed conditions, and is eligible for potential preclinical, development, regulatory, and commercial milestone payments, for a potential total consideration of up to USD ~2.5 billion, with the majority representing commercial milestones, plus tiered royaltiesSHANGHAI, Dec. 11, 2025 /PRNewswir
- PRZealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseasesPress release – No. 18 / 2025 Zealand Pharma and OTR Therapeutics enter multi-program strategic collaboration and license agreement to develop novel therapeutics for metabolic diseases Collaboration will combine Zealand Pharma's expertise in obesity and metabolic health with OTR Therapeutics' proprietary oral small-molecule platform and strong drug discovery capabilities, to discover and develop novel therapeutics for multiple targets in metabolic diseasesOTR Therapeutics will receive an initial upfront payment of USD 20 million, which may increase to USD 30 million under certain pre-agreed conditions, and is eligible for potential preclinical, development, regulatory, and commercial mile
- PRTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCompany announcement – No. 24 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 5, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attache
ZEAL FAQ
7 questionsWhat does Zealand Pharma A/S do?
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has...Where does ZEAL stock trade?
Zealand Pharma A/S (ZEAL) is listed on NASDAQ.What sector and industry is ZEAL in?
Zealand Pharma A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Zealand Pharma A/S go public?
Zealand Pharma A/S (ZEAL) completed its IPO in 2017.What are analysts saying about ZEAL?
Zealand Pharma A/S has had 4 recent analyst actions on file. The most recent action was from Berenberg: Buy on 2024-03-05.What companies are similar to ZEAL?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ZEAL side-by-side with any of them on Quantisnow.How can I track ZEAL on Quantisnow?
Quantisnow aggregates Zealand Pharma A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ZEAL to receive live email and push alerts on every new disclosure.